Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Arch Ophthalmol. 2012 Mar;130(3):336–341. doi: 10.1001/archopthalmol.2011.1503

Figure 3.

Figure 3

Inhibition of tumor growth in Tyr-tag mice receiving TSP1-anti-angiogenic mimetic peptide. The 3 week-old Tyr-Tag mice received TSP1 antiangiogenic mimetic peptide or vehicle for 5 weeks (100 mg/Kg/day, 5 days a week) and tumor volumes were evaluated as described in Methods. Histological sections showed a significant decrease in size of tumor in mice receiving the peptide compared to vehicle. The original magnification was x40. The quantification of tumor areas in mice receiving TSP1 peptide indicated that the tumor areas were approximately 10-fold smaller than the tumor areas of mice receiving vehicle (P< 0.05; n=10).